PATENT CLAIM ANALYSIS

Application Number: 15780328
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "228200"]

Abstract:
The present disclosure provides for methods for preparing tricyclic PI3K inhibitor compounds in high yield and purity in aqueous solvent systems.

Claim (Index 81):
A method for treating cancer in a patient wherein the cancer is characterized by the overexpression of PI3 kinase, the method comprising administering a therapeutically effective amount of a PI3 kinase inhibitor compound of Formula III to a person in need of such treatment, wherein Formula III has a structure wherein X 1  is S, O, N, NR 6 , CR 1 , C(R 1 ) 2 , or \u2014C(R 1 ) 2 O\u2014; X 2  is C, CR 2  or N; X 3  is C, CR 3  or N; A is a 5, 6, or 7-membered carbocyclyl or heterocyclyl ring fused to X 2  and X 3 , optionally substituted with one or more R 5 , R 10  or R 15  groups; R 6  is H, C 1 -C 12  alkyl, C 2 -C 8  alkenyl, C 2 -C 8  alkynyl, \u2014(C 1 -C 12  alkylene)-(C 3 -C 12  carbocyclyl), \u2014(C 1 -C 12  alkylene)(\u2014C 2 -C 20  heterocyclyl), \u2014(C 1 -C 12  alkylene)-C(\u2550O)\u2014(C 2 -C 20  heterocyclyl), (C 1 -C 12  alkylene)-(C 6 -C 20  aryl), and \u2014(C 1 -C 12  alkylene)-(C 1 -C 20  heteroaryl), where alkyl, alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, \u2014CH 3 , \u2014CH 2 CH 3 , \u2014C(CH 3 ) 3 , \u2014CH 2 OH, \u2014CH 2 CH 2 OH, \u2014(CH 3 ) 2 OH, \u2014CH 2 OCH 3 , \u2014CN, \u2014CO 2 H, \u2014COCH 3 , \u2014COC(CH 3 ) 3 , \u2014CO 2 CH 3 , \u2014CONH 2 , \u2014CONHCH 3 , \u2014CON(CH 3 ) 2 , \u2014C(CH 3 ) 2 CONH 2 , \u2014NO 2 , \u2014NH 2 , \u2014NHCH 3 , \u2014N(CH 3 ) 2 , \u2014NHCOCH 3 , \u2014NHS(O) 2 CH 3 , \u2014N(CH 3 )C(CH 3 ) 2 CONH 2 , \u2014N(CH 3 )CH 2 CH 2 S(O) 2 CH 3 , \u2550O, \u2014OH, \u2014OCH 3 , \u2014S(O) 2 N(CH 3 ) 2 , \u2014SCH 3 , \u2014S(O) 2 CH 3 , cyclopropyl, cyclobutyl, oxetanyl, morpholino, and 1,1-dioxo-thiopyran-4-yl; R 1 , R 2 , and R 3  are independently selected from H, F, Cl, Br, I, \u2014CH 3 , \u2014CH 2 CH 3 , \u2014C(CH 3 ) 3 , \u2014CH 2 OH, \u2014CH 2 CH 2 OH, \u2014C(CH 3 ) 2 OH, \u2014CH 2 OCH 3 , \u2014CN, \u2014CF3, \u2014CO 2 H, \u2014COCH 3 , \u2014COC(CH 3 ) 3 , \u2014CO 2 CH 3 , \u2014CONH 2 , \u2014CONHCH 3 , \u2014CON(CH 3 ) 2 , \u2014C(CH 3 ) 2 , \u2014CONH 2 , \u2014NO 2 , \u2014NH 2 , \u2014NHCH 3 , \u2014N(CH 3 ) 2 , \u2014NHCOCH 3 , \u2014NHS(O) 2 CH 3 , \u2014N(CH 3 )C(CH 3 )CONH 2 , \u2014N(CH 3 )CH 2 CH 2 S(O) 2 CH 3 , \u2550O, \u2014OH, \u2014OCH 3 , \u2014S(O) 2 N(CH 3 ) 2 , \u2014SCH 3 , \u2014S(O) 2 CH 3 , cyclopropyl, cyclobutyl, oxetanyl, morpholino, and 1,1-dioxo-thiopyran-4-yl; R 4  is selected from C 6 -C 20  aryl, C 2 -C 20  heterocyclyl and C 1 -C 20  heteroaryl, each of which are optionally substituted with one or more groups independently selected from F, Cl, Br, I, \u2014CH 3 , \u2014CH 2 CH 3 , \u2014CH(CH 3 ) 2 , \u2014CH 2 CH(CH 3 ) 2 , \u2014CH 2 CH 3 , \u2014CH 2 CN, \u2014CN, \u2014CF 3 , \u2014CH 2 OH, \u2014CO 2 H, \u2014CONH 2 , CONH(CH 3 ), \u2014CON(CH 3 ), \u2014NO 2 , \u2014NH 2 , \u2014NHCH 3 , \u2014NHCOCH 3 , \u2014OH, \u2014OCH 3 , \u2014OCH 2 CH 3 , \u2014OCH(CH 3 ) 2 , \u2014SH, \u2014NHC(O)NHCH 3 , \u2014NHC(O)NHCH 2 CH 3 , \u2014NHS(O) 2 CH 3 , \u2014N(CH 3 )C(O)OC(CH 3 ) 3 , \u2014S(O) 2 CH 3 , benzyl, benzyloxy, morpholinyl, morpholinomethyl, and 4-methylpiperazin-1-yl; each R 5 , R 10  and R 15  is independently selected from C 1 -C 12  alkyl, C 2 -C 8  alkenyl, C 2 -C 8  alkynyl, \u2014(C 1 -C 12  alkylene)-(C 3 -C 12  carbocyclyl), \u2014(C 1 -C 12  alkylene)-(C 2 -C 20  heterocyclyl), \u2014(C 1 -C 12  alkylene)-C(O)\u2014(C 2 -C 20  heterocyclyl), \u2014(C 1 -C 12  alkylene)-(C 6 -C 20  aryl), and \u2014(C 1 -C 12  alkylene)-(C 1 -C 20  heteroaryl); or two geminal R 5 , R 10  and/or R 15  groups form a 3, 4, 5, or 6-membered carbocyclyl or heterocyclyl ring, where alkyl, alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, \u2014CH 3 , \u2014CH 2 CH 3 , \u2014C(CH) 3 \u2014CH 2 OH, \u2014CH 2 CH 2 OH, \u2014C(CH 3 ) 2 OH, \u2014CH 2 OCH 3 , \u2014CN, \u2014CH 2 F, \u2014CHF 2 , \u2014CF 3 , \u2014CO 2 H, \u2014COCH 3 , \u2014COC(CH 3 ) 3 , \u2014CO 2 CH 3 , \u2014CONH 2 , \u2014CONHCH 3 , \u2014CON(CH 3 ) 2 , \u2014C(CH 3 ) 2 CONH 2 , \u2014NO 2 , \u2014NH 2 , \u2014NHCH 3 , \u2014N(CH 3 ) 2 , \u2014NH\u2014COCH 3 , \u2014NHS(O) 2 CH 3 , \u2014N(CH 3 )C(CH 3 ) 2 CONH 2 , \u2014N(CH 3 )CH 2 CH 2 S(O) 2 CH 3 , \u2550O, \u2014OH, \u2014OCH 3 , \u2014S(O)N(CH 3 ) 2 , \u2014SCH 3 , \u2014S(O) 2 CH 3 , cyclopropyl, cyclobutyl, oxetanyl, morpholino, and 1,1-dioxo-thiopyran-4-yl; and mor is selected from: wherein mor is optionally substituted with one or more R 7  groups independently selected from F, CI, Br, I, \u2014CH 3 , \u2014CH 2 CH 3 , \u2014CH 2 CH 2 CH 3 , \u2014CH(CH 3 ) 2 , \u2014C(CH 3 ) 3 , \u2014CH 2 OCH 3 , \u2014CHF 2 , \u2014CN, \u2014CF 3 , \u2014CH 2 OH, \u2014CH 2 OCH 3 , \u2014CH 2 CH 2 OH, \u2014CH 2 C(CH 3 ) 2 OH, \u2014CH(CH 3 )OH, \u2014CH(CH 2 CH 3 )OH, \u2014CH 2 CH(OH)CH 3 , \u2014C(CH 3 ) 2 OH, \u2014C(CH 3 ) 2 OCH 3 , \u2014CH(CH 3 )F, \u2014C(CH 3 )F 2 , \u2014CH(CH 2 CH 3 )F, \u2014C(CH 2 CH 3 ) 2 F, \u2014CO 2 H, \u2014CONH 2 , \u2014CON(CH 2 CH 3 ) 2 , \u2014COCH 3 , \u2014CON(CH 3 ) 2 , \u2014NO 2 , \u2014NH 2 \u2014NHCH 3 , \u2014N(CH 3 ) 2 , \u2014NHCH 2 CH 3 , \u2014NHCH(CH 3 ) 2 , \u2014NHCH 2 CH 2 OH, \u2014NHCH 2 CH 2 OCH 3 , \u2014NHCOCH 3 , \u2014NHCOCH 2 CH 3 , \u2014NHCOCH 2 OH, \u2014NHS(O) 2 CH 3 , \u2014N(CH 3 )S(O) 2 CH 3 , \u2550O, \u2014OH, \u2014OCH 3 , \u2014OCH 2 CH 3 , \u2014OCH(CH 3 ) 2 , \u2014SH, \u2014NHC(O)NHCH 3 , \u2014NHC(O)NHCH 2 CH 3 , \u2014S(O)CH 3 , \u2014S(O)CH 2 CH 3 , \u2014S(O)CH 3 , \u2014S(O)NH 2 , \u2014S(O) 2 NHCH 3 , \u2014S(O) 2 N(CH 3 ) 2 , and \u2014CH 2 S(O) 2 CH 3 .

Metadata:
- Claim Count in Document: 22.0
- Percentile: 93.0
- Lexical Diversity: 1.1
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14524204', '14972333', '13018068', '12586241', '14930929']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7967976847264651
- 35 USC 102 Novelty (BERT): 0.5097091101836781
- Combined Prediction Score: 0.7680888272721864
- Mean Citation Score: 302.856558
- Max Citation Score: 309.51782000000014
- Similarity Product: 255.96373530833847

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test